Meeting goals

• Provide participants – Current status regarding• Classification• Diagnosis• Management

– Update on the latest developments in neuroendocrine tumors (NETs)

• Address key open questions & controversies in the management of NETs

• Present characteristic clinical cases

ENETS GUIDELINESLatest 2015 updated

ENETS Consensus

Naming Consistency Tissue of origin

Diagnosing Nature of disease WHO classification

Grading Biological behavior Proliferative fraction *

Staging Disease extension TNM staging

TNM classification

TNM classification

Targeting NETs – Data from Phase III studies

• Somatostatin receptors highly expressed by NETs

– Targeting SSTRs can provide besides symptom also disease control

• New potential targets :– mTOR, PI3K, VEGF inhibitors– Other antiangiogenic agents

• Targeted & combination treatments evolving

Long acting - somatostatin analogs

Sunitinib

Everolimus Bevacizumab

Multidisciplinary team achievements

• Improved 5 year survival– UK colorectal & esophageal cancer

• Improved 2 year survival– UK neck & head cancer

• Improved 7 year relative survival– Sweden breast cancer

Gastroenterologists

Geneticists

Endocrinologists

Surgeons

Research nurses

Oncologists

Radiologists –Nuclear Medicine

Pathologists

Target audience – Multidisciplinary team (MDT)

NET patient

Advances of MDT management of NETs

• Accurate diagnosis and staging• Evaluation of performance status and quality of

life• Consensus regarding patient’s care plan• Cohesive delivery of support, therapy and

information on prognosis• Continous reassesment, discussion, and peer

review of individualized care plan